Valuation Kintor Pharmaceutical Limited OTC Markets
Stocks
KNTPF
KYG5273B1077
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3420 USD | +22.10% |
|
+22.10% | +58.33% |
| 06-10 | Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939 | MT |
| 05-28 | Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares | RE |
Company Valuation: Kintor Pharmaceutical Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 3,253 | 3,884 | 3,899 | 662.1 | 394.7 | 869.2 |
| Change | - | 19.37% | 0.39% | -83.02% | -40.39% | 120.26% |
| Enterprise Value (EV) 1 | 2,082 | 2,987 | 3,308 | 458 | 379 | 923.1 |
| Change | - | 43.46% | 10.77% | -86.16% | -17.25% | 143.58% |
| P/E | -5.36x | -4.24x | -3.44x | -0.6x | -2.53x | -3.96x |
| PBR | 2.16x | 2.35x | 2.61x | 1.42x | 1.35x | 4.76x |
| PEG | - | -0.1x | -0.47x | 0.25x | 0x | -0.2x |
| Capitalization / Revenue | - | 113,459,524x | - | - | 78,930,130x | 26,597,148x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -5.54x | -3.61x | -3.46x | -0.43x | -2.95x | -6.55x |
| EV / EBIT | -5.49x | -3.58x | -3.41x | -0.43x | -2.67x | -5.35x |
| EV / FCF | -6.9x | -3.34x | -4.85x | -3.82x | -2.73x | -12.9x |
| FCF Yield | -14.5% | -30% | -20.6% | -26.2% | -36.6% | -7.77% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.643 | -2.363 | -2.534 | -2.472 | -0.3605 | -0.4449 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 34.23 | - | - | 5 | 32.68 |
| EBITDA 1 | -375.6 | -828 | -956.4 | -1,056 | -128.6 | -140.9 |
| EBIT 1 | -379 | -834.7 | -969.1 | -1,070 | -141.8 | -172.5 |
| Net income 1 | -508.3 | -842.1 | -954.4 | -1,061 | -155.3 | -200.1 |
| Net Debt 1 | -1,171 | -897 | -590.6 | -204.1 | -15.68 | 53.86 |
| Reference price 2 | 8.808 | 10.020 | 8.713 | 1.480 | 0.912 | 1.761 |
| Nbr of stocks (in thousands) | 369,390 | 387,590 | 447,500 | 447,500 | 432,965 | 493,525 |
| Announcement Date | 4/29/21 | 4/27/22 | 4/28/23 | 4/29/24 | 4/29/25 | 4/29/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.29x | 8.39x | 25.35x | 0.06% | 54.44B | |
| 17.19x | 5.15x | 11.19x | 1.75% | 45.8B | |
| -17.98x | 4.24x | -7.4x | -.--% | 22.98B | |
| -36.23x | 11.97x | -34.9x | -.--% | 20.76B | |
| 20.05x | 3.91x | 10.15x | -.--% | 16.25B | |
| 21.54x | 4.32x | 14.29x | -.--% | 15.34B | |
| 16.41x | 4.73x | 11.09x | -.--% | 13.05B | |
| -434.11x | 29.51x | -3290.08x | -.--% | 12.37B | |
| 41.21x | 15.94x | 46.81x | -.--% | 12.47B | |
| Average | -37.73x | 9.79x | -357.05x | 0.2% | 23.72B | |
| Weighted average by Cap. | -12.21x | 8.40x | -180.78x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 9939 Stock
- KNTPF Stock
- Valuation Kintor Pharmaceutical Limited
Select your edition
All financial news and data tailored to specific country editions
